Medical News

RSS

AmerisourceBergen first quarter revenues increase 3% to record $19.9 billion

AmerisourceBergen Corporation today reported that in its fiscal year 2011 first quarter, ended December 31, 2010, diluted earnings per share were $0.57, a 10 percent increase. Revenue in the quarter was a record $19.9 billion, up 3 percent.

4 Feb 2011

FDA approves ANDA for phentermine HCl 37.5 mg tablets

Elite Pharmaceuticals, Inc. announced today the approval of an Abbreviated New Drug Application for phentermine HCl 37.5 mg tablets by the U.S. Food and Drug Administration. The phentermine HCl tablets are the generic equivalent of the Adipex-P 37.5 mg tablets.

4 Feb 2011

Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

4 Feb 2011

HPV vaccine can prevent 90% of genital warts in men: Study

The vaccine for human papillomavirus can prevent 90 percent of genital warts in men when offered before exposure to the four HPV strains covered by the vaccine, according to a new multi-center study led by H. Lee Moffitt Cancer Center and UCSF.

4 Feb 2011

Senior citizens can benefit from new emergency detection system

Elderly people living alone have a dangerous life: after a fall, they often spend hours lying on the floor before their situation comes to anyone's attention and a doctor is contacted. A new system automatically detects predicaments like this and informs a trusted person. This makes it possible to live an independent life in one's own four walls.

4 Feb 2011

Opinions: Global Fund; Accountability for Haiti Aid

Washington Post columnist Michael Gerson writes of the "breathless Associated Press story" about the uncovering of some corruption in grants given by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the subsequent reaction: "When scandals fit preexisting ideological narratives, they assume a life of their own. This particular narrative - the story of useless, wasted aid - is durable. It is also misleading and might be deadly."

4 Feb 2011

Positive results from Photocure's Allumera RevitAll study to improve skin's appearance

Photocure, a Norwegian specialty pharmaceutical company focused in dermatology and cancer, today announced positive results from its consumer trial with Allumera™, a breakthrough cosmetic treatment formulated to improve the skin's appearance.

4 Feb 2011

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed, Inc., today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor. The clinical data were published in the December 3, 2010 on-line issue of the American Association for Cancer Research journal, Clinical Cancer Research, and are expected to appear soon in the print version of the publication.

4 Feb 2011

General Dynamics to collaborate with MPT to offer EHR solution to DoD

General Dynamics Information Technology, a business unit of General Dynamics, has entered into a letter of intent with McKesson Provider Technologies to collaborate in offering an Electronic Health Record solution known as the "Way Ahead" to the Department of Defense.

4 Feb 2011

Savient closes sale of $230M 4.75% Convertible Senior Notes due 2018

Savient Pharmaceuticals, Inc. today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.

4 Feb 2011

MedQuist Holdings prices initial public offering of common stock at $8.00 per share

MedQuist Holdings Inc., formerly CBaySystems Holdings Limited, a leading provider of integrated clinical documentation solutions for the U.S. Healthcare system, today announced the pricing of its U.S. initial public offering of 4,500,000 shares of its common stock at a price to the public of $8.00 per share.

4 Feb 2011

ECR launches sleep aid product, Zolpimist Oral Spray in the US

NovaDel Pharma Inc. today announced that Zolpimist Oral Spray has been launched in the United States by ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal Co., Inc.. ECR Pharmaceuticals announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate.

4 Feb 2011

FDA clears new mobile radiology application

A new mobile radiology application cleared today by the U.S. Food and Drug Administration will allow physicians to view medical images on the iPhone and iPad manufactured by Apple Inc.

4 Feb 2011

Hologic receives FDA approval for hydroxyprogesterone caproate injection

Hologic, a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the U.S. Food and Drug Administration has approved Hologic's pharmaceutical named Makena, formerly known as Gestiva.

From Hologic, Inc. 4 Feb 2011

Research roundup: Comparing profit and nonprofit hospice care; Hospital mortality and spending; High-deductible insurance plans

Association Of Hospice Agency Profit Status With Patient Diagnosis, Location of Care, and Length of Stay - "The current Medicare Hospice Benefit reimburses hospices at a fixed per diem rate that does not consider the patient's diagnosis, location of care, or hospice LOS [length-of-stay]," and as such, "profit can be maximized by caring for patients with certain diagnoses that require fewer skilled services, patients residing in nursing homes, or patients with longer hospice stays."

4 Feb 2011

Incisive Surgical, Innocutis sign marketing agreement for INSORB Absorbable Skin Stapler

Innocutis Medical, a dermatology company focused on novel surgical devices and specialty pharmaceuticals, is pleased to announce an exclusive marketing agreement with Incisive Surgical, for the sales and marketing rights within the dermatology market for the patented INSORB Absorbable Skin Stapler, a revolutionary new modality for skin closure.

4 Feb 2011

Dermatologists offer preventative tips to minimize pesky skin problems caused by plants

What may start as a seemingly harmless day of gardening or yard work can quickly take a turn for the worse when common plants make their mark on the skin, causing a host of mild to even severe skin reactions. That is why dermatologists are arming outdoor enthusiasts with preventative tips to keep these perils of the great outdoors at arm's length.

4 Feb 2011

ECR announces availability of Zolpimist Oral Spray in the U.S.

ECR Pharmaceuticals Co., Inc., a subsidiary of Hi-Tech Pharmacal Co., Inc. announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate.

4 Feb 2011

Scientists discover how stressed cells boost thrombin production

In our not-so-distant evolutionary past, stress often meant imminent danger, and the risk of blood loss, so part of our body's stress response is to stock-pile blood-clotting factors. Scientists in the Molecular Medicine Partnership Unit, a collaboration between the European Molecular Biology Laboratory in Heidelberg, Germany, and the University of Heidelberg Medical Centre, have discovered how stressed cells boost the production of the key blood-clotting factor, thrombin.

4 Feb 2011

BIOTRONIK launches Reliaty pacing system analyzer in Europe

BIOTRONIK SE & Co. KG, today announced the European launch of the Reliaty pacing system analyzer after CE approval and successful pre-market evaluation. The pacing system analyzer is used during an implantation of implantable pacemakers, implantable cardioverter-defibrillators and Cardiac Resynchronization Therapy systems to ensure adequate lead placement, maintenance of basic cardiac functions, and to evaluate pacing parameters for customized device programming.

4 Feb 2011